Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Journal of Gastroent...arrow_drop_down
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
Journal of Gastroenterology and Hepatology
Article . 2003 . Peer-reviewed
License: Wiley Online Library User Agreement
Data sources: Crossref
HKU Scholars Hub
Article . 2010
Data sources: HKU Scholars Hub
versions View all 3 versions
addClaim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Cholangiocarcinoma in liver cirrhosis

Authors: Lai, CL; Tso, WK; Ng, IOL; Yuen, MF; Hui, CK; Chan, AOO;

Cholangiocarcinoma in liver cirrhosis

Abstract

AbstractBackground and Aim: Hepatocellular carcinoma (HCC) is usually associated with chronic liver diseases and liver cirrhosis, while conversely, cholangiocarcinoma (CC) usually occurs in a non‐cirrhotic liver. The purpose of the present study was to evaluate CC in liver cirrhosis.Methods: Between January 1998 and December 1999, 26 patients with CC were retrospectively reviewed. The occurrence of CC in chronic hepatitis B infection‐related liver cirrhosis, portal vein thrombosis (PVT) and survival were analyzed.Results: Twenty‐six patients with CC (19 with a non‐cirrhotic liver and seven with chronic hepatitis B infection‐related liver cirrhosis) were included in the present study. All cases of CC in the cirrhotic group were incidentally discovered during routine screening for HCC. The mean age (± SD) was 58.8 ± 14 years in the cirrhotic group and 73.2 ± 15.9 years (P = 0.001) in the non‐cirrhotic group. When compared to the cirrhotic group, the non‐cirrhotic group had a higher median level of albumin (42 compared to 30 g/L, P = 0.005), bilirubin (117.5 compared to 18 µmol/L, P = 0.01), alkaline phosphatase (291.5 compared to 100 U/L, P = 0.001) and gamma glutamyl transpeptidases (215.5 compared to 31 U/L, P = 0.001). In contrast, the cirrhotic group had a higher median prothrombin time (PT) compared to the non‐cirrhotic group (18.2 compared to 12 s, P = 0.05). In the non‐cirrhotic group, only one patient (5.3%) showed evidence of PVT on a computerized tomography and Doppler ultrasound, while in the cirrhotic group six patients (85.7%) had PVT (P < 0.001). The median survival period in the cirrhotic group was six months (range 2–24 months) compared to 16 months (range 6–41 months) in the non‐cirrhotic group (P = 0.036).Conclusion: CC in cirrhotic liver presented at a younger age and patients who developed CC were prone to PVT. The survival period was also shorter in comparison to that of non‐cirrhotic liver patients.

Country
China (People's Republic of)
Related Organizations
Keywords

Biological Markers - blood, Adult, Liver Cirrhosis, Male, Intrahepatic - pathology - radiography - ultrasonography, Antineoplastic Agents - administration & dosage, Biopsy, 610, Cholangiocarcinoma - complications - mortality - therapy, Antineoplastic Agents, Cholangiocarcinoma, Endoscopic Retrograde, Median survival, 80 and over, alpha-Fetoproteins - metabolism, Humans, Chemoembolization, Therapeutic, Tomography, Ultrasonography, Aged, Aged, 80 and over, Cholangiopancreatography, Endoscopic Retrograde, Bile Duct Neoplasms - complications - mortality - therapy, Platelet Count, Doppler, Liver Cirrhosis - complications - mortality - therapy, Ultrasonography, Doppler, Middle Aged, Hepatitis B, Portal vein thrombosis, Survival Analysis, Bile Ducts, Intrahepatic - pathology - radiography - ultrasonography, X-Ray Computed, Cholangiopancreatography, Treatment Outcome, Bile Ducts, Intrahepatic, Bile Duct Neoplasms, Liver cirrhosis, Prothrombin Time, Hong Kong, Chemoembolization, Female, Bile Ducts, Therapeutic, Tomography, X-Ray Computed, Biomarkers

  • BIP!
    Impact byBIP!
    citations
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    16
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Top 10%
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
citations
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
16
Average
Top 10%
Average
Upload OA version
Are you the author? Do you have the OA version of this publication?